openPR Logo
Press release

Global Tuberculosis Drugs Market, By Therapy Type (First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy), and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024

06-26-2017 04:42 PM CET | Health & Medicine

Press release from: Pharma & Healthcare Industry

Global Tuberculosis Drugs Market, By Therapy Type (First Line

Tuberculosis Drugs: Hopes Pinned on Renewed Government Investments in Emerging Economies

Tuberculosis is a chronic condition that is often undermined, though it can be fatal if left unchecked. Thankfully, extensive awareness campaigns and initiatives by various governments to curb the menace is bearing fruit. Tuberculosis treatment helped prevent 49 million fatalities associated with the condition between 2000 and 2015. However, there are still some prominent diagnostic and treatment slits that continue. In 2015, approximately 6.1 million newly diagnosed tuberculosis cases were reported by national authorities of various countries and reported to World Health Organization. This high increase in tuberculosis cases during 2013–2015, was typically due to a 34% increase in tuberculosis cases notifications in India. Globally, there was 4.3 million new tuberculosis cases gap between incident and reported cases, out of which India, Indonesia, and Nigeria comprises almost half of these newly diagnosed cases impacting high revenue generation in tuberculosis drugs market.

Request Sample of Global Tuberculosis Drugs Market : https://www.coherentmarketinsights.com/insight/request-sample/191

In 2015, out of 580 thousand people who were eligible for multidrug resistance tuberculosis treatment, only 125 000 (20%) were registered. Five countries, namely India, China, the Russian Federation, Indonesia, and Nigeria account for over 60% of this gap. Worldwide, the multidrug resistance tuberculosis treatment success rate was 50-52% in 2013 and in 2015, approximately 55% of reported new tuberculosis patients had a documented HIV test result. The HIV-positive tuberculosis patients on an antiretroviral therapy was around 78%. This led to the wider understanding about the ailment and government and non-governmental organizations alike are focusing on developing tuberculosis preventive treatment and increasing their access to the general populace. Thus, it would boost the tuberculosis drugs market over the forecast period.
The global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to witness a CAGR of 23.4% during the forecast period (2016 – 2024).

With the significant increase in revenue of tuberculosis drugs market, over last decade, more than 10 chemical moiety have advanced into the clinical trial development pipeline, which include six new chemical moiety significantly and specifically developed for tuberculosis. Though there are molecules in clinical development phase, the global drug pipeline for tuberculosis is still not sufficient to address the unmet needs of treatment. Many pharmaceutical companies have produced molecules that are under clinical trials and the key challenges by any company to develop new product to treat tuberculosis and effects the tuberculosis drugs market are the needs for drugs in combination therapy, new trial strategies, studies on pediatric TB drugs, population and increased clinical trial capacity and clear regulatory guidelines.

Get an exclusive discount on this report : https://www.coherentmarketinsights.com/insight/request-discount/191

High funding for research and development and clinical trials drugs to boost the tuberculosis drugs market

There was around US$ 6.6 billion revenue accessible for tuberculosis care and prevention in many of the low and middle-income countries in 2016, out of which 84% was from domestic sources. However, national tuberculosis program (NTPs) in low income countries linger to depend on international donors or foreign healthcare agencies to fund them approximately 90%. Investments in low income countries and middle income countries declined by US$ 2 billion to US$ 8.3 billion, which was needed in 2016. There were many enhancements needed in overall healthcare financing to curb new tuberculosis cases proportionally boosting tuberculosis drugs market. Government expenditures on healthcare in specific to tuberculosis in 2014 were less than the World Health Organization set a benchmark of at least 6% of gross domestic product in around 150 countries. Private expenditures surpassed 45% of total healthcare expenditures in tuberculosis in 46 countries, which also includes 11 of the 30 high tuberculosis burden countries. Presently, there are around 13 vaccine candidates in clinical development, which include trial drugs for prevention of tuberculosis infection and trial drugs for prevention of tuberculosis disease in people with Latent Tuberculosis Disease. According to WHO, at least US$ 2 billion investment is needed every year for tuberculosis research and development. In stark contrast, capital investment during 2005–2014 was reported to be US$ 0.7 billion annually. Infusion of investments in research and development would significantly improve the tuberculosis drugs market outlook.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
E-mail:sales@coherentmarketinsights.com
Website:https://www.coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Tuberculosis Drugs Market, By Therapy Type (First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy), and Geography - Insights, Opportunity Analysis, and Industry Forecast till 2024 here

News-ID: 596233 • Views: 173

More Releases from Pharma & Healthcare Industry

Thalidomide Market - Global Industry Insights, Trends, Outlook, and Opportunity …
Worldwide Market Reports added Latest Research Report titled "Thalidomide Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026" to its Large Report database. Thalidomide is an immunomodulatory drug and a prototype of the thalidomide class of drugs. It is mainly used in the treatment of certain cancers (multiple myeloma) and of a complication of leprosy. It is sold under the brand name Immunoprin. It has many applications in the
Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Rx Medical Food Trends Estimates High Demand by 2024
Medical food is a category of products for dietary management or supportive therapy for specific disease or medical conditions such as pulmonary and metabolic disorders. Ingredients used in medical foods must have generally recognized as safe (GRAS) status, which is assigned to naturally found food materials. Medical food is different from nutritional food, dietary supplements, and prescription drugs. Medical food is protein-based, nutrient-based (Omega 3 fatty acids, chelated zinc, and
Specialty CRO's Market - Regional Insights
On the basis of geography, global specialty CROs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to dominate the market over the forecast period, owing to the fact that pharmaceutical and biotech companies in this region spends significant amount on research and development, in order to bring novel therapies to the market. Click To Continue Reading; https://www.coherentmarketinsights.com/ongoing-insight/specialty-cros-market-1627 As per the estimation

All 5 Releases


More Releases for Tuberculosis

Tuberculosis Drugs Market Industry Forecast till 2024
Tuberculosis is a chronic condition that is often undermined, though it can be fatal if left unchecked. Thankfully, extensive awareness campaigns and initiatives by various governments to curb the menace is bearing fruit. Tuberculosis treatment helped prevent 49 million fatalities associated with the condition between 2000 and 2015. However, there are still some prominent diagnostic and treatment slits that continue. In 2015, approximately 6.1 million newly diagnosed tuberculosis cases were
Tuberculosis Vaccine Market Opportunity Analysis, 2018-2026
Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of
Tuberculosis Diagnosis and Treatment Market
The Global Tuberculosis diagnosis and treatment market is relied upon to develop at a CAGR of 2.3 % amid 2017-2022. An irresistible illness caused by the bacterium Mycobacterium tuberculosis (MTB) is known as Tuberculosis (TB). Tuberculosis by and large influences the lungs yet can likewise influence different parts of the body. Inert tuberculosis is the sort of TB which don't have indications. Around 10% of inert contaminations advance to dynamic
Global Tuberculosis Diagnostics Sales Market Report 2018
The Global Tuberculosis Diagnostics Sales Market Report 2018 is a professional and in-depth study on the current state of the Tuberculosis Diagnostics industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Tuberculosis Diagnostics Industry analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This
Tuberculosis Testing Market | Analysis & Trends 2020
Key players in the Global Tuberculosis (TB) Testing Market, according to a report by Transparency Market Research, are Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Hain Lifescience GmbH, Hologic Inc. QIAGEN, Abbott Laboratories, Alere Inc., Epistem plc, Cepheid, bioMérieux SA, Akonni Biosystems Inc., and Sanofi. Among them, the top players namely, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, and Hain Lifescience GmbH
Tuberculosis Testing Market to Increasing Tuberculosis Awareness and Control Pro …
A new Transparency Market Research report states that the global tuberculosis testing market stood at US$1.9 bn in 2013 and is predicted to reach US$2.6 bn by 2020. It is predicted to expand at a CAGR of 4.30% from 2014 to 2020. The title of the report is “Tuberculosis Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020.” As per the report, the rising acceptance